Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets
Maaike Rijkers,
David Schmidt,
Nina Lu,
Cynthia S.M. Kramer,
Sebastiaan Heidt,
Arend Mulder,
Leendert Porcelijn,
Frans H.J. Claas,
Frank W.G. Leebeek,
A.J. Gerard Jansen,
Ilse Jongerius,
Sacha S. Zeerleder,
Gestur Vidarsson,
Jan Voorberg,
Masja de Haas
Affiliations
Maaike Rijkers
Department of Cellular and Molecular Hemostasis, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
David Schmidt
Department of Experimental Immunohaematology, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
Nina Lu
Department of Cellular and Molecular Hemostasis, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
Cynthia S.M. Kramer
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center
Sebastiaan Heidt
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center
Arend Mulder
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center
Leendert Porcelijn
Department of Immunohaematology Diagnostics, Sanquin Diagnostic Services, Amsterdam
Frans H.J. Claas
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center
Frank W.G. Leebeek
Department of Hematology, Erasmus University Medical Center, Rotterdam
A.J. Gerard Jansen
Department of Cellular and Molecular Hemostasis, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam;Department of Hematology, Erasmus University Medical Center, Rotterdam
Ilse Jongerius
Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
Sacha S. Zeerleder
Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
Gestur Vidarsson
Department of Experimental Immunohaematology, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam
Jan Voorberg
Department of Cellular and Molecular Hemostasis, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, University of Amsterdam;Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam
Masja de Haas
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center;Department of Immunohaematology Diagnostics, Sanquin Diagnostic Services, Amsterdam;Center for Clinical Transfusion Research, Sanquin, Leiden, the Netherlands
High titers of HLA antibodies are associated with platelet refractoriness, causing poor platelet increments after transfusions in a subset of patients with HLA antibodies. Currently, we do not know the biological mechanisms that explain the variability in clinical responses in HLA alloimmunized patients receiving platelet transfusions. Previously we showed that a subset of anti-HLA IgG-antibodies induces FcγRIIa-dependent platelet activation and enhanced phagocytosis. Here, we investigated whether anti-HLA IgG can induce complement activation on platelets. We found that a subset of anti-HLA IgG induced complement activation via the classical pathway, causing C4b and C3b deposition and formation of the membrane-attack complex. This resulted in permeabilization of platelet membranes and increased calcium influx. Complement activation also caused enhanced α-granule release, as measured by CD62P surface exposure. Blocking studies revealed that platelet activation was caused by FcγRIIa-dependent signaling as well as HLA antibody induced complement activation. Synergistic complement activation employing combinations of monoclonal IgGs suggested that assembly of oligomeric IgG complexes strongly promoted complement activation through binding of IgGs to different antigenic determinants on HLA. In agreement with this, we observed that preventing anti-HLA-IgG hexamer formation using an IgG-Fc:Fc blocking peptide, completely inhibited C3b and C4b deposition. Our results show that HLA antibodies can induce complement activation on platelets including membrane attack complex formation, pore formation and calcium influx. We propose that these events can contribute to fast platelet clearance in vivo in patients refractory to platelet transfusions with HLA alloantibodies, who may benefit from functional-platelet matching and treatment with complement inhibitors.